archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited is a global biotherapy industry leader.
    Home Home Page Our Products We develop and manufacture vaccines and plasma protein biotherapies These products help treat and prevent a range of human medical conditions Read more Features Our Corporate Responsibility Report 2013 This report highlights CSL s global performance in key priority areas Annual General Meeting 2013 CSL held its AGM in Melbourne on October 16 The webcast is now available for on demand viewing News CSL signs

    Original URL path: http://www.csl.com.au/ (2014-01-05)
    Open archived version from archive


  • All CSL Websites
    be referred to may not comply with Australian regulatory requirement or regulatory requirement in the place in which you are located Please check with your local country to see if products or programs are available in your area CSL Businesses CSL Behring CSL Biotherapies CSL Behring CSL Behring Austria CSL Behring Belgium Luxembourg CSL Behring Brazil CSL Behring Canada CSL Behring China CSL Behring France CSL Behring Germany CSL Behring

    Original URL path: http://www.csl.com.au/csl-websites (2014-01-05)
    Open archived version from archive

  • Subscribe to CSL Limited News Alerts
    Nordic Spain Switzerland UK USA CSL Plasma US CSL Plasma Germany About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Subscribe to News Alert RSS Feeds CSL Limited press releases are available as RSS feeds To access use this link Latest Press Releases Or paste the following link into your RSS aggregator Latest Press Releases note in order to see

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649922/content/1196562649495/content.htm (2014-01-05)
    Open archived version from archive

  • CSL Ltd is a leader in plasma protein biotherapeutics
    Home About CSL About CSL The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies With major facilities in Australia Germany Switzerland and the US CSL has over 10 000 employees working in 27 countries Our Areas of Expertise Plasma Products Human plasma is used to produce a wide range of life saving medicines Our various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma derived products The key businesses involved with plasma products include CSL Behring is a global provider of plasma derived recombinant products We operate one of the world s largest plasma collection networks through CSL Plasma CSL Behring Australia is the chosen national plasma fractionator of Australia New Zealand Hong Kong Malaysia Singapore and Taiwan We also manufacture and market in vitro diagnostic products through bioCSL Immunohaematology Vaccines Pharmaceuticals We manufacture and provide influenza vaccine globally In Australia and New Zealand bioCSL also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products

    Original URL path: http://www.csl.com.au/about (2014-01-05)
    Open archived version from archive

  • CSL Limited is a partner of choice for companies worldwide
    CSL business For many serious and life saving medical products we are a partner of choice for many companies around the world Headquarters in Melbourne Australia the CSL Group includes bioCSL incorporating Immunohaematology CSL Behring incorporating CSL Plasma Key business areas Research and Development In 2006 07 we invested over AUD 190m in this part of our business Our centres of excellence are located around the world and they focus on Developing new products Improving existing products Find out more about Research Development Plasma products CSL is a leading manufacturer in a US 7 5 billion plasma industry A continual focus on innovation in new products improved products and manufacturing know how is the key to future growth The key businesses involved with plasma products include CSL Behring is a global provider of plasma derived recombinant products We operate one of the world s largest plasma collection networks through CSL Plasma CSL Behring is the chosen national plasma fractionator of Australia New Zealand Hong Kong Malaysia Singapore and Taiwan Vaccines and pharmaceuticals CSL is also a major manufacturer in a US 2 billion influenza industry with 40 years manufacturing experience and sales spanning 27 countries around the globe In addition

    Original URL path: http://www.csl.com.au/businesses (2014-01-05)
    Open archived version from archive

  • CSL Ltd products provide treatment of serious medical conditions
    Our Product Areas Learn More Product Finder Complete product list Product Pipeline We produce a range of life saving products that enable many thousands of people around the world to lead normal healthy lives In Australia bioCSL manufactures and in licenses markets and distributes vaccines with particular focus on vaccines for the prevention and treatment of serious disease CSL Behring Australia supports all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma derived products CSL Behring is the chosen national fractionator of Australia New Zealand Hong Kong Malaysia Singapore and Taiwan Visit our Product Finder to view the range of products in the following areas Plasma derived therapies Vaccines Antivenoms Diagnostics products Pharmaceuticals Overview of CSL Behring s product areas Plasma derived Therapies Used to treat bleeding disorders infections and autoimmune diseases Also used to treat patients in critical care settings Just as our products vary from country to country so does the information we can lawfully provide Overview of bioCSL s product areas Vaccines Used to induce immunity to protect people against a range of viral and bacterial diseases Antivenoms Used to treat victims of venomous snake

    Original URL path: http://www.csl.com.au/products (2014-01-05)
    Open archived version from archive

  • CSL Limited R&D for Plasma Therapeutics & protein based medicines
    in R D Core Capabilities Global R D Network Product Pipeline Clinical Trials Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home Research and Development Research and Development Contact CSL R D CSL is a global specialty biopharmaceutical company that aims to identify develop and commercialise important new biotherapeutic products that help to save lives by preventing or treating serious medical conditions CSL are committed to significantly investing in its future R D portfolio and capabilities in the areas of immunoglobulins specialty products haemophilia products and breakthrough medicines CSL s strong commitment to funding research and development of protein based medicines for unmet medical needs underpins its continued growth CSL operates as one integrated global research and development organisation CSL assembles co ordinated global project teams drawing together staff from different countries depending on their expertise These teams rely on a project management framework that facilitates collaboration across national and cultural boundaries R D Partnerships To complement in house expertise CSL also draws on strategic partnerships with academic institutions and other organisations globally These collaborative partnerships support a range of effective research programs including both basic and applied research in plasma derived and recombinant protein based product development R

    Original URL path: http://www.csl.com.au/research-development (2014-01-05)
    Open archived version from archive

  • CSL’s strategic partnerships support innovative research
    partnerships with academic institutions and other companies in Australia Asia North America and Europe These collaborative partnerships support a range of innovative research programs including both basic and applied research in plasma therapeutics vaccines and recombinant biotechnology Experience Internal Capabilities CSL has access to enabling technologies to support early stage research opportunities CSL s research is also backed by development capabilities around the world CSL conducts scientific advisory panels and clinical trials in many countries and has the benefit of years of experience in major regulatory jurisdictions CSL also has significant manufacturing capabilities of complex R D and in market biopharmaceuticals Furthermore CSL has the commercialisation experience in specialist niche areas to offer successful product launches Strengthening the Pipeline The Research Development activities at CSL are focused on new product development life cycle management and safety of our extensive product portfolio CSL invests in the development of protein based medicines for treating serious human diseases that can be made from plasma traditional biological sources or using recombinant biotechnology CSL is interested in building its Research Development portfolio particularly in the areas of Oncology Inflammation Immunology and Coagulation Factors Partnership Types CSL forms licensing partnerships around innovative product candidates and technologies

    Original URL path: http://www.csl.com.au/business-development (2014-01-05)
    Open archived version from archive